The estimated Net Worth of Torben Lund Hansen is at least $1.14 Milione dollars as of 28 August 2024. Torben Hansen owns over 50,000 units of Y-Mabs Therapeutics Inc stock worth over $1,135,912 and over the last 6 years he sold YMAB stock worth over $0. In addition, he makes $0 as Senior Vice President e Chief Technical Officer at Y-Mabs Therapeutics Inc.
Torben has made over 1 trades of the Y-Mabs Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of YMAB stock worth $219,000 on 28 August 2024.
The largest trade he's ever made was exercising 50,000 units of Y-Mabs Therapeutics Inc stock on 28 August 2024 worth over $219,000. On average, Torben trades about 5,556 units every 0 days since 2018. As of 28 August 2024 he still owns at least 85,600 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Torben Hansen stock trades at the bottom of the page.
Dr. Torben Lund-Hansen, Ph.D., is the Senior Vice President, Chief Technical Officer of the Company. Dr. Lund-Hansen has served as our Senior Vice President, Chief Technical Officer since January 2016. Dr. Lund-Hansen has substantial experience in antibody process development, commercial manufacturing and global project management. Dr. Lund-Hansen was Vice President and Head of Manufacturing from 2002 to 2006, Vice President and Head of Manufacturing and Preclinical Safety from 2006 to 2008, Senior Vice President, Technical Operations from 2008 to 2009 at Genmab and President and Treasurer at Genmab MN Inc., a wholly owned subsidiary of Genmab located near Minneapolis-St. Paul, Minnesota, from 2008 to 2009. At Genmab, Dr. Lund-Hansen was responsible for outsourcing of clinical and commercial drug substance and drug product manufacturing. He was also President and Treasurer from 2008 to 2009 of Genmab MN Inc. Dr. Lund-Hansen was the owner of Lund-Hansen Consulting ApS from 2009 to 2016, where he provided consulting services related to manufacturing processes for biopharmaceutical-related industries. Dr. Lund-Hansen has been responsible for compiling technical Chemistry, Manufacturing, and Controls documentation packages submitted to global regulatory agencies followed by approval and launch of several biologics. Dr. Lund-Hansen received his M.Sc. and Ph.D. from the University of Copenhagen.
Torben Hansen is 69, he's been the Senior Vice President e Chief Technical Officer of Y-Mabs Therapeutics Inc since 2016. There are 1 older and 18 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
Torben's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad e Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: